icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Paris France
11-15 April 2018
Back grey_arrow_rt.gif
 
 
 
Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combination with Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial
 
 
  Reported by Jules Levin
EASL 2018 April 11-15 Paris France
 
Lena Allweiss, Claudia Dettmer, Tassilo Volz, Katja Giersch, Alexander Alexandrov, Heiner Wedemeyer, Stephan Urban, Jan-Hendri Bockmann, Marc Lutgehetmann, Maura Dandri
 
EASL: Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of MyrcludexB in combination with Tenofovirin patients with HBV/HDV coinfection - (05/01/18)

0501181

0501182

0501183

0501184

0501185

0501186

0501187

0501188

0501189

05011810

05011811